Perhaps one of the greatest success stories in cancer prevention is cervical cancer screening. Generations of women, particularly in high-income countries, have benefited from cytology-based annual testing, also known as Pap tests. In the last 10 years, screening guidelines have shifted to include testing for human papillomavirus (HPV), the cause of cervical cancer.
In February 2017, DCEG experts and colleagues from around the world presented the evidence in favor of phasing out cytology-based screening in favor of the more sensitive HPV testing. A collection of articles published in a special issue of the journal Preventive Medicine lays out their reasoning, as well as the challenges to implementation around the world.
Reference: "Emerging Paradigms in Cervical Cancer Screening” (Special Issue), guest editor: Mark Schiffman, MD, MPH. Individual articles have been published in advance of Preventive Medicine, Volume 98 (May 2017), Elsevier.